Protalix BioTherapeutics Logo
US74365A3095
A2PWSL
PLX

Protalix BioTherapeutics

Previsioni

Il prezzo obiettivo medio degli analisti è 5,47 € (+107,98%). La mediana è 5,47 € (+107,98%).

Acquista
  5
Mantieni
  2
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Protalix reports strong revenue and profit growth in Q2 2026, stock slightly lower premarket

    Protalix increased revenue in the second quarter to $19.9 million (+26.8%) and reported a net profit of $3.8 million (EPS $0.05). Product sales were driven primarily by Elfabrio to Chiesi; the company holds $40.7 million in cash and is debt-free. Management reaffirmed the 2026 revenue guidance but noted variable ordering patterns from partners and a pipeline that is still maturing; top-line data for PRX-115 are expected in H2 2027. The stock fell modestly by 0.41% in premarket trading. » Altro su de.investing.com


  • Protalix beats revenue expectations but misses EPS and shares plunge

    Protalix reported Q4 2025 revenue of $52.74 million versus expected $18.35 million, but missed on earnings per share at -$0.08 (forecast $0.035). The stock fell about 13% in premarket trading after the company reported a net profit swing to a $6.6 million loss for the fiscal year. Higher R&D costs (+51% to $19.6 million) and increased cost of sales weighed on profitability, while sales to Pfizer supported the strong revenue. Protalix expects a $25 million milestone payment and sees opportunities from a potential European approval of a new Elfabrio dosing regimen. » Altro su de.investing.com


  • Protalix partners with Secarna to develop antisense therapies for rare kidney diseases

    Protalix and Secarna have entered a collaboration and option agreement to develop antisense oligonucleotide therapies for rare kidney diseases. Protalix will identify pharmaceutical targets, Secarna will use its AI platform OligoCreator to design candidate molecules, and Protalix will receive an exclusive license option for clinical development and commercialization. The agreement marks Protalix’s first expansion into rare kidney diseases using RNA technologies; financial terms were not disclosed. Protalix also reported a Q3 2025 EPS and revenue miss versus analyst expectations. » Altro su de.investing.com


  • Protalix misses Q3 2025 earnings forecast, stock falls sharply premarket

    Protalix reported Q3 2025 earnings per share of $0.03, missing the $0.07 expectation; quarterly revenue was $17.67 million versus an estimated $17.79 million. The stock fell 13.55% in premarket trading to $1.85. For the first nine months, the company reported revenue growth of 24% to $43.6 million and held $29.4 million in cash; Protalix plans to start a phase 2 study for PRX-115 before year-end with initial results expected in Q3 2027. » Altro su de.investing.com


  • Protalix and Chiesi seek re-evaluation of negative EMA opinion on Elfabrio

    Protalix and Chiesi Global Rare Diseases have requested a re-evaluation of the EMA’s negative opinion on the proposed alternative dosing regimen for Elfabrio. The aim is to approve an additional option of 2 mg/kg every four weeks alongside the existing 1 mg/kg every two weeks for the treatment of adult patients with Fabry disease. The current marketing authorization remains in effect during the procedure; the final decision will be made by the European Commission after the review is completed. Elfabrio carries a warning for hypersensitivity reactions; Protalix will publish quarterly results on November 17. » Altro su de.investing.com

Dati finanziari

Nell'ultimo trimestre, Protalix BioTherapeutics ha registrato ricavi pari a 19,36 Mln € e un utile netto di 3,5 Mln €

(EUR) settembre 2026
YoY
Ricavi 19,36 Mln 27,25%
Utile lordo 12,4 Mln 52,78%
Utile netto 3,5 Mln 74,26%
EBITDA 4,47 Mln 88,09%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
232,07 Mln €
Numero di azioni
84,32 Mln
Massimo/minimo a 52 settimane
2,91 € - 1,50 €
Dividendi No
Beta
0,01
Rapporto P/E
11,61
Rapporto PEG
-0,02
Rapporto P/B
3,02
Rapporto P/S
3,01

Profilo aziendale

Protalix BioTherapeutics, Inc., una società biofarmaceutica, si occupa dello sviluppo e della commercializzazione di proteine terapeutiche ricombinanti basate sul proprio sistema proprietario di espressione proteica su cellule vegetali ProCellEx negli Stati Uniti, in Australia, Canada, Israele, Brasile, Russia, Turchia e a livello internazionale. La società offre Elelyso per il trattamento della malattia di Gaucher. Il suo portafoglio di prodotti in sviluppo comprende PRX-102, un candidato a proteina terapeutica, che si trova nell'ultima fase di sperimentazioni cliniche per il trattamento della malattia di Fabry; PRX-110, una forma ricombinante proprietaria di desossiribonucleasi I umana espressa su cellule vegetali, che ha completato le sperimentazioni cliniche di fase IIa per il trattamento della fibrosi cistica; PRX-115, un'uricasi ricombinante PEGilata espressa su cellule vegetali per il trattamento della gotta; e PRX-119, un candidato prodotto a base di DNasi I umana ricombinante PEGilata espressa su cellule vegetali per il trattamento di malattie correlate ai NET. La società ha accordi e partnership con Pfizer, Fundação Oswaldo Cruz (Fiocruz) e Chiesi Farmaceutici S.p.A. La società è stata fondata nel 1993 e ha sede a Hackensack, nel New Jersey.

Nome
Protalix BioTherapeutics
CEO
Dror Bashan
Sede centrale Hackensack, nj
Israele
Sito web
Settore
Beni di prima necessità
Industria
Prodotti alimentari
Quotazione in borsa
15/05/1998
Dipendenti 226

Simboli di borsa

Borsa Simbolo
AMEX
PLX
Frankfurt
PBDA.F
Düsseldorf
PBDA.DU
München
PBDA.MU
🍪

Parqet  usa i cookie. Scopri di più